Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?

#1778

Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.

Aim(s): To analyze chemotherapeutic treatment for LCNEC on a population basis.

Materials and methods: The Netherlands pathology registry (PALGA) and cancer registry (IKNL) were searched for patients with LCNEC diagnosed between 2003-2012. In 207 patients tumour slides were available for panel-revision. Data on clinical characteristics and chemotherapy were retrieved. First-line platinum combined chemotherapy was clustered: 1) gemcitabine, docetaxel, paclitaxel or vinorelbine as NSCLC type, 2) pemetrexed as pem-NSCLC type, and 3) etoposide as SCLC type.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Derks J

Authors: Derks J, Suylen R, Thunnissen E, Den Bakker M, Groen H,

Keywords: lcnec, chemotherapy, nec, lung,